1. Metabolic Disease

Metabolic Disease

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Metabolic Disease Related Products (2256):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17471A
    Metformin hydrochloride 1115-70-4 99.98%
    Metformin hydrochloride (1,1-Dimethylbiguanide hydrochloride) inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin hydrochloride triggers autophagy.
    Metformin hydrochloride
  • HY-15371
    Forskolin 66575-29-9 98.52%
    Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase. Forskolin is also an inducer of intracellular cAMP formation. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy. Forskolin is also a potent exosome biogenesis and/or secretion activator.
    Forskolin
  • HY-P0035
    Insulin (human) 11061-68-0
    Insulin (human) is a polypeptide hormone that regulates the level of glucose.
    Insulin (human)
  • HY-B2176
    ATP 56-65-5 >98.0%
    ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo, provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation.
    ATP
  • HY-A0190
    Ceruletide 17650-98-5 99.96%
    Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts.
    Ceruletide
  • HY-50202
    Etomoxir 124083-20-1 99.65%
    Etomoxir ((R)-(+)-Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
    Etomoxir
  • HY-17386
    Rosiglitazone 122320-73-4 99.54%
    Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3.
    Rosiglitazone
  • HY-100116A
    Mitoquinone mesylate 845959-50-4 >98.0%
    Mitoquinone mesylate is a TPP-based, mitochondrially targeted antioxidant in order to protect against oxidative damage.
    Mitoquinone mesylate
  • HY-13443
    Exendin-4 141758-74-9 99.85%
    Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
    Exendin-4
  • HY-B0240
    Disulfiram 97-77-8 98.67%
    Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells[1-4].
    Disulfiram
  • HY-15409
    Empagliflozin 864070-44-0 99.93%
    Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
    Empagliflozin
  • HY-P1156
    Insulin(cattle) 11070-73-8 98.60%
    Insulin cattle (Insulin from bovine pancreas) is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.
    Insulin(cattle)
  • HY-10450
    Dapagliflozin 461432-26-8 99.96%
    Dapagliflozin (BMS-512148), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
    Dapagliflozin
  • HY-N0750
    Monocrotaline 315-22-0 >98.0%
    Monocrotaline is an pyrrolizidine alkaloid extracted from the seeds of the Crotalaria spectabilis plant to induce pulmonary hypertension in rodents.
    Monocrotaline
  • HY-100596
    AS1842856 836620-48-5 98.89%
    AS1842856, a specific Foxo1 inhibitor (IC50=30 nM), potently suppresses autophagy. AS1842856 inhibits FoxO1 activity by suppressing the expression of SIRT1. AS1842856 only reduces the activity of FoxO1 by binding with it, without affecting its transcription and protein expression.
    AS1842856
  • HY-P0014
    Liraglutide 204656-20-2 99.71%
    Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
    Liraglutide
  • HY-50108
    GW 4064 278779-30-9 99.76%
    GW 4064 is a potent FXR agonist with an EC50 of 65 nM.
    GW 4064
  • HY-13992
    AP20187 195514-80-8 99.80%
    AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.
    AP20187
  • HY-B0445
    NAD+ 53-84-9 99.99%
    NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+
  • HY-16737
    Elafibranor 923978-27-2 99.18%
    Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively.
    Elafibranor